High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes

Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies. The presence of antibodies to individual AAV serotypes is typically detected...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Matthew R. Gardner, Desiree E. Mendes, Claudia P. Muniz, José M. Martinez-Navio, Sebastian P. Fuchs, Guangping Gao, Ronald C. Desrosiers
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2022-03-01
Serie:	Molecular Therapy: Methods & Clinical Development
Soggetti:	adeno-associated virus AAV capsid serotype ELISA neutralization assay
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2329050122000043
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!